Free Trial
LON:ORPH

Open Orphan (ORPH) Share Price, News & Analysis

Open Orphan logo
GBX 10 +0.50 (+5.26%)
(As of 10/25/2022)

About Open Orphan Stock (LON:ORPH)

Key Stats

Today's Range
9.50
10.38
50-Day Range
10
10
52-Week Range
8.68
25
Volume
652,639 shs
Average Volume
1.56 million shs
Market Capitalization
£67.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Open Orphan Plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers. The Disease in Motion platform has various potential applications across a range of end users, including big technology, wearables, pharma, and biotech companies. Further, the company provides pre­clinical and early clinical research services; sales and marketing services; and biometry, data management, and statistics to its various European pharmaceutical clients, as well as drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), and PK and medical writing to a range of European clients. The company is headquartered in London, the United Kingdom.

Receive ORPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Open Orphan and its competitors with MarketBeat's FREE daily newsletter.

ORPH Stock News Headlines

Octopus Investments Increases Stake in hVIVO PLC
New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar
As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.
See More Headlines

ORPH Stock Analysis - Frequently Asked Questions

Open Orphan's stock was trading at GBX 10 on January 1st, 2024. Since then, ORPH shares have increased by 0.0% and is now trading at GBX 10.
View the best growth stocks for 2024 here
.

Shares of ORPH stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Open Orphan investors own include HSBC (HSBA), Royal Dutch Shell (RDSB), Cassava Sciences (SAVA), Barclays (BARC), EQTEC (EQT), Grafton Group (GFTU) and Lloyds Banking Group (LLOY).

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
CIK
N/A
Fax
N/A
Employees
179
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£34.71 million
Cash Flow
GBX 2.40 per share
Book Value
GBX 3.10 per share

Miscellaneous

Free Float
N/A
Market Cap
£67.09 million
Optionable
Not Optionable
Beta
N/A
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (LON:ORPH) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners